Business Description
Provectus Biopharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US74373P1084
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | -8.78 | |||||
Debt-to-Equity | -0.41 | |||||
Debt-to-EBITDA | -1.2 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 16.4 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 15.7 | |||||
3-Year Book Growth Rate | 38.1 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
12-1 Month Momentum % | -15.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.1 | |||||
Quick Ratio | 0.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 | |||||
Shareholder Yield % | -1.1 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -206.33 | |||||
ROIC % | -63.14 | |||||
ROC (Joel Greenblatt) % | -3045.35 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -19.12 | |||||
EV-to-EBITDA | -19.19 | |||||
EV-to-FCF | -15.69 | |||||
Earnings Yield (Greenblatt) % | -5.22 | |||||
FCF Yield % | -6.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Provectus Biopharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.005 | ||
Beta | 0.68 | ||
Volatility % | 25 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 0.045 | ||
12-1 Month Momentum % | -15.89 | ||
52-Week Range (€) | 0.045 - 0.057 | ||
Shares Outstanding (Mil) | 419.91 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Provectus Biopharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Provectus Biopharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Provectus Biopharmaceuticals Inc Frequently Asked Questions
What is Provectus Biopharmaceuticals Inc(STU:PXY)'s stock price today?
When is next earnings date of Provectus Biopharmaceuticals Inc(STU:PXY)?
Does Provectus Biopharmaceuticals Inc(STU:PXY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |